What’s So Great About STAR*D?

Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.


Treatment for depression costs the United States a staggering $83 billion each year. Part of this is due to the fact that the treatments themselves involve so much trial and error; there’s very little reliable information out on the effectiveness of various drugs and forms of therapy.

So it’s good news that today Slate is reporting on a new study called STAR*D, conducted by the National Institute of Mental Health, that compares and contrasts the twenty options for prescription antidepressants, their dosages, and even the effects of psychotherapy — something no other study has ever done. For the 19 million Americans who suffer from depression, this is a major step forward. The pharmaceutical industry usually doesn’t produce any comparative data on depression, a state of affairs that has previously left most patients and their doctors guessing which treatment will be the best fit.

Comparative, independent trials will also enable doctors to rely less on collected by the pharmaceutical industry. Mark Gibson, deputy director of the Center for Evidence-Based Policy at Oregon Health and Science University, adds that in regards to data provided by drug firms, “it’s not unusual for less than 10 percent of studies to meet our standards of quality.” And according to Jerry Avorn, professor of medicine at Harvard, comparative studies could motivate drug companies to develop more advanced versions of current drugs, improving on what we already have.

THIS IS BIG FOR US.

And we won't beat around the bush: Our fundraising drive to finish our current budget on June 30 and start our new fiscal year on July 1 is lagging behind where we need it to be.

If you value the reporting you get from Mother Jones and you can right now, please consider joining your fellow readers with a donation to help make it all possible. Whether you can pitch in $5 or $500, it all matters.

If you're new to Mother Jones or aren't yet sold on supporting our nonprofit reporting, please take a moment to read Monika Bauerlein's post about our priorities after these chaotic several years, and why this relatively quiet moment is also an urgent one for our democracy and Mother Jones’ bottom line—and if you find it compelling, please join us.

payment methods

THIS IS BIG FOR US.

And we won't beat around the bush: Our fundraising drive to finish our current budget on June 30 and start our new fiscal year on July 1 is lagging behind where we need it to be.

If you value the reporting you get from Mother Jones and you can right now, please consider joining your fellow readers with a donation to help make it all possible. Whether you can pitch in $5 or $500, it all matters.

If you're new to Mother Jones or aren't yet sold on supporting our nonprofit reporting, please take a moment to read Monika Bauerlein's post about our priorities after these chaotic several years, and why this relatively quiet moment is also an urgent one for our democracy and Mother Jones’ bottom line—and if you find it compelling, please join us.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate